Philippe Rodon

2.9k total citations
29 papers, 698 citations indexed

About

Philippe Rodon is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Philippe Rodon has authored 29 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 12 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Philippe Rodon's work include Multiple Myeloma Research and Treatments (17 papers), Cancer Treatment and Pharmacology (10 papers) and Lymphoma Diagnosis and Treatment (5 papers). Philippe Rodon is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Cancer Treatment and Pharmacology (10 papers) and Lymphoma Diagnosis and Treatment (5 papers). Philippe Rodon collaborates with scholars based in France, United States and Belgium. Philippe Rodon's co-authors include Thierry Façon, B. Grosbois, Brigitte Pegourié, Philippe Moreau, Jean‐Luc Harousseau, Lotfi Benboubker, Olivier Decaux, Laurent Garderet, Chantal Doyen and Philippe Casassus and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Philippe Rodon

28 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philippe Rodon France	9	483	433	356	150	83	29	698
Sascha A. Tuchman United States	17	605 1.3×	506 1.2×	436 1.2×	98 0.7×	47 0.6×	77	955
Elias Kiwan United States	8	591 1.2×	443 1.0×	379 1.1×	76 0.5×	27 0.3×	12	765
Bradley Augustson Australia	11	502 1.0×	282 0.7×	312 0.9×	186 1.2×	127 1.5×	43	684
Niels Frost Andersen Denmark	17	371 0.8×	425 1.0×	294 0.8×	103 0.7×	32 0.4×	42	756
Per Trøllund Pedersen Denmark	13	313 0.6×	191 0.4×	251 0.7×	85 0.6×	67 0.8×	28	463
Howard R. Terebelo United States	14	473 1.0×	312 0.7×	309 0.9×	129 0.9×	61 0.7×	74	716
Ghulam Rehman Mohyuddin United States	13	342 0.7×	226 0.5×	317 0.9×	63 0.4×	39 0.5×	129	629
Zandra Klippel United States	14	523 1.1×	436 1.0×	505 1.4×	56 0.4×	31 0.4×	34	790
Andrew Belch United States	15	839 1.7×	425 1.0×	535 1.5×	239 1.6×	138 1.7×	32	1.1k
Michela Ceccolini Italy	11	625 1.3×	387 0.9×	441 1.2×	75 0.5×	37 0.4×	21	734

Countries citing papers authored by Philippe Rodon

Since Specialization

Citations

This map shows the geographic impact of Philippe Rodon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Rodon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Rodon more than expected).

Fields of papers citing papers by Philippe Rodon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Rodon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Rodon. The network helps show where Philippe Rodon may publish in the future.

Co-authorship network of co-authors of Philippe Rodon

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Rodon. A scholar is included among the top collaborators of Philippe Rodon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Rodon. Philippe Rodon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benboubker, Lotfi, Anne‐Marie Stoppa, Philippe Rodon, et al.. (2020). Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study. Blood. 136(Supplement 1). 25–26.

Leleu, Xavier, Guillemette Fouquet, Lionel Karlin, et al.. (2017). Carfilzomib weekly-melphalan-prednisone in untreated elderly multiple myeloma: IFM2012-03.. Journal of Clinical Oncology. 35(15_suppl). 8004–8004. 1 indexed citations

Pegourié, Brigitte, Gilles Pernod, Lionel Karlin, et al.. (2017). Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT).. Journal of Clinical Oncology. 35(15_suppl). 8019–8019. 7 indexed citations

Malak, Sandra, Pascale Cony‐Makhoul, Jean‐Christophe Ianotto, et al.. (2016). Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM). Blood. 128(22). 3123–3123. 3 indexed citations

Dartigeas, Caroline, Eric Van Den Neste, Hervé Maisonneuve, et al.. (2016). Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly (≥ 65 years) CLL patients: Results of the randomized CLL 2007 SA trial from the French FILO Group (NCT00645606).. Journal of Clinical Oncology. 34(15_suppl). 7505–7505. 5 indexed citations

Corso, Alessandro, Michel Delforge, Kevin Song, et al.. (2015). HEALTH RESOURCE UTILIZATION WITH CONTINUOUS LENALIDOMIDE TREATMENT (TX) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). Haematologica. 100. 24–25. 1 indexed citations

Rodon, Philippe, Cyrille Hulin, Brigitte Pegourié, et al.. (2012). Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial. Blood. 120(21). 4044–4044. 5 indexed citations

Houot, Roch, Steven Le Gouill, Christiane Mounier, et al.. (2011). Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Annals of Oncology. 23(6). 1555–1561. 36 indexed citations

Leleu, Xavier, Philippe Rodon, Cyrille Hulin, et al.. (2011). Final Analysis of MELISSE, a Large Multicentric Observational Study to Determine Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Treated with Immunomodulator Drugs. Blood. 118(21). 1235–1235. 1 indexed citations

10.

Gressin, Rémy, Roch Houot, Mario Ojeda‐Uribe, et al.. (2010). Final Results of the RiPAD+C Regimen Including Velcade In Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group.. Blood. 116(21). 2791–2791. 3 indexed citations

11.

Leleu, Xavier, Philippe Rodon, Cyrille Hulin, et al.. (2010). MELISSE, a Large Multicentric Observational Study to Determine Criteria and Risk Factors of Thromboembolism for Patients with Multiple Myeloma Treated with Immunomodulator Drugs. Blood. 116(21). 809–809. 2 indexed citations

12.

Hulin, Cyrille, Thierry Façon, Philippe Rodon, et al.. (2009). Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. Journal of Clinical Oncology. 27(22). 3664–3670. 266 indexed citations

13.

Terrier, Benjamin, Arnaud Jaccard, Jean‐Luc Harousseau, et al.. (2008). The Clinical Spectrum of IgM-Related Amyloidosis. Medicine. 87(2). 99–109. 54 indexed citations

14.

Spaëth, Dominique, B Desablens, Philippe Rodon, et al.. (2008). Epoetin β Once-Weekly Therapy in Anemic Patients with Solid Tumors and Non-Myeloid Hematological Malignancies Receiving Chemotherapy. Oncology. 74(1-2). 112–118. 5 indexed citations

15.

Hulin, C., O. Decaux, Valérie Coiteux, et al.. (2008). MELPHALAN-PREDNISONE-THALIDOMIDE (MP-T) DEMONSTRATES A SIGNIFICANT SURVIVAL ADVANTAGE IN ELDERLY PATIENTS >75 YEARS WITH MULTIPLE MYELOMA COMPARED WITH MELPHALAN-PREDNISONE (MP) IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, IFM01/01. European Journal of Internal Medicine. 19. S14–S15. 2 indexed citations

16.

Decaux, O., et al.. (2007). Épidémiologie descriptive des gammapathies monoclonales. Expérience d'un centre hospitalier général et d'un service de médecine interne de centre hospitalier et universitaire. La Revue de Médecine Interne. 28(10). 670–676. 8 indexed citations

17.

Hulin, Cyrille, Thierry Façon, Philippe Rodon, et al.. (2007). Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01.. Blood. 110(11). 75–75. 39 indexed citations

18.

Façon, Thierry, Jean‐Luc Harousseau, F. Huguet, et al.. (2006). Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Journal of Clinical Oncology. 24(18_suppl). 1–1. 148 indexed citations

19.

Rodon, Philippe, et al.. (2003). Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath‐1H. European Journal Of Haematology. 70(5). 319–321. 30 indexed citations

20.

Rodon, Philippe, Claude Linassier, Jean‐Bernard Gauvain, et al.. (2001). Multiple myeloma in elderly patients: presenting features and outcome. European Journal Of Haematology. 66(1). 11–17. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact